{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:50:29Z","timestamp":1793893829054,"version":"4.8.0"},"reference-count":19,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,4,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The utility of posttreatment bone marrow biopsy (BMB) histology to confirm complete response (CR) in lymphoma clinical trials is in question. We retrospectively evaluated the impact of BMB on response assessment in immunochemotherapy-treated patients with previously untreated follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) in the phase 3 Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM; NCT01332968) and A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA; NCT01287741) trials, respectively. Baseline BMB was performed in all patients, with repeat BMBs in patients with a CR by computed tomography (CT) at end of induction (EOI) and a positive BMB at baseline, to confirm response. Positron emission tomography imaging was also used in some patients to assess EOI response (Lugano 2014 criteria). Among patients with an EOI CR by CT in GALLIUM and GOYA, 2.8% and 4.1%, respectively, had a BMB-altered response. These results suggest that postinduction BMB histology has minimal impact on radiographically (CT)-defined responses in both FL and DLBCL patients. In GALLIUM and GOYA, respectively, 4.7% of FL patients and 7.1% of DLBCL patients had a repeat BMB result that altered response assessment when applying Lugano 2014 criteria, indicating that bone marrow evaluation appears to add little value to response assessment in FL; however, its evaluation may still have merit in DLBCL.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019001261","type":"journal-article","created":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T19:01:46Z","timestamp":1587063706000},"page":"1589-1593","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":23,"title":["Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1064-7727","authenticated-orcid":false,"given":"Sarah C.","family":"Rutherford","sequence":"first","affiliation":[{"name":"Department of Medicine, Weill Cornell Medicine, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Herold","sequence":"first","affiliation":[{"name":"Helios Klinikum Erfurt, Erfurt, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hiddemann","sequence":"first","affiliation":[{"name":"Department of Medicine III, Ludwig-Maximilians University Hospital Munich, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lale","family":"Kostakoglu","sequence":"first","affiliation":[{"name":"Department of Radiology and Medical Imaging, University of Virginia Health System, Charlottesville, VA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Marcus","sequence":"first","affiliation":[{"name":"King\u2019s College Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Martelli","sequence":"first","affiliation":[{"name":"Department of Translational and Precision Medicine, Hematology Section, \u201cSapienza\u201d University, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie H.","family":"Sehn","sequence":"first","affiliation":[{"name":"BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6952-6073","authenticated-orcid":false,"given":"Marek","family":"Trn\u011bn\u00fd","sequence":"first","affiliation":[{"name":"First Faculty of Medicine, Charles University General Hospital, Prague, Czech Republic;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Trotman","sequence":"first","affiliation":[{"name":"Concord Repatriation General Hospital, University of Sydney, Concord, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7772-2747","authenticated-orcid":false,"given":"Umberto","family":"Vitolo","sequence":"first","affiliation":[{"name":"Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia-Istituto di Ricovero e Cura a Carattere Scientifico, Candiolo, Turin, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Nielsen","sequence":"first","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Mattiello","sequence":"first","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz","family":"Sahin","sequence":"first","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gila","family":"Sellam","sequence":"first","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Martin","sequence":"first","affiliation":[{"name":"Department of Medicine, Weill Cornell Medicine, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,4,16]]},"reference":[{"issue":"4","key":"2020041611381290400_B1","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020041611381290400_B2","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020041611381290400_B3","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.blre.2015.06.003","article-title":"Opportunities and limitations of bone marrow biopsy and bone marrow FDG-PET in lymphoma","volume":"29","author":"Adams","year":"2015","journal-title":"Blood Rev"},{"issue":"8","key":"2020041611381290400_B4","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.2967\/jnumed.112.114710","article-title":"In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET\/CT provides better diagnostic performance and prognostic stratification than does biopsy","volume":"54","author":"Berthet","year":"2013","journal-title":"J Nucl Med"},{"issue":"1","key":"2020041611381290400_B5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2012-12-473389","article-title":"PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement","volume":"122","author":"Khan","year":"2013","journal-title":"Blood"},{"issue":"9","key":"2020041611381290400_B6","doi-asserted-by":"crossref","first-page":"e2910","DOI":"10.1097\/MD.0000000000002910","article-title":"The value of PET\/CT in detecting bone marrow involvement in patients with follicular lymphoma","volume":"95","author":"Perry","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"2020041611381290400_B7","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14071","article-title":"(18) F-FDG PET-CT and trephine biopsy assessment of bone marrow involvement in lymphoma","volume":"174","author":"Ujjani","year":"2016","journal-title":"Br J Haematol"},{"issue":"2","key":"2020041611381290400_B8","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/bjh.14839","article-title":"Bone marrow biopsies do not impact response assessment for follicular lymphoma patients treated on clinical trials","volume":"179","author":"Rutherford","year":"2017","journal-title":"Br J Haematol"},{"issue":"14","key":"2020041611381290400_B9","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"issue":"31","key":"2020041611381290400_B10","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","article-title":"Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma","volume":"35","author":"Vitolo","year":"2017","journal-title":"J Clin Oncol"},{"issue":"27","key":"2020041611381290400_B11","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"2020041611381290400_B12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/bjh.14996","article-title":"Minimal residual disease in non-Hodgkin lymphoma - current applications and future directions","volume":"180","author":"Chase","year":"2018","journal-title":"Br J Haematol"},{"issue":"24","key":"2020041611381290400_B13","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.1158\/1078-0432.CCR-14-0407","article-title":"Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial","volume":"20","author":"Galimberti","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"23","key":"2020041611381290400_B14","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1182\/blood-2013-06-507319","article-title":"Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program","volume":"122","author":"Ladetto","year":"2013","journal-title":"Blood"},{"issue":"22","key":"2020041611381290400_B15","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1182\/blood.V128.22.613.613","article-title":"Minimal residual disease in patients with follicular lymphoma treated with obinutuzumab or rituximab as first-line induction immunochemotherapy and maintenance in the phase 3 GALLIUM study","volume":"128","author":"Pott","year":"2016","journal-title":"Blood"},{"key":"2020041611381290400_B16","first-page":"7557","article-title":"Relationship between MRD and PET responses and PFS in previously untreated follicular lymphoma in the GALLIUM trial","volume-title":"J Clin Oncol","author":"Trotman","year":"2018"},{"issue":"6","key":"2020041611381290400_B17","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1080\/14737159.2017.1319765","article-title":"The value of liquid biopsy in diagnosis and monitoring of diffuse large b-cell lymphoma: recent developments and future potential","volume":"17","author":"Camus","year":"2017","journal-title":"Expert Rev Mol Diagn"},{"issue":"7","key":"2020041611381290400_B18","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/bloodadvances.2017015164","article-title":"Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma","volume":"2","author":"Delfau-Larue","year":"2018","journal-title":"Blood Adv"},{"issue":"28","key":"2020041611381290400_B19","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/8\/1589\/1724466\/advancesadv2019001261.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/8\/1589\/1724466\/advancesadv2019001261.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T19:01:52Z","timestamp":1587063712000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/8\/1589\/454387\/Impact-of-bone-marrow-biopsy-on-response"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,16]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,4,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019001261","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,16]]}}}